Systemic treatment of mice with the nucleoside analog 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine [aciclovir]) was found to be highly effective against acute type 1 herpes simplex virus infection of the pinna. The drug ablated clinical signs and reduced virus replication both in tissue local to the inoculation site and within the nervous system. Provided that moderate-sized virus inocula were used, acycloguanosine treatment reduced or prevented the establishment of a latent infection in the dorsal root ganglia relating to the sensory nerve supply of the ear. However, although it aborted artificially produced infections in dorsal root ganglia, acycloguanosine was found not to be effective against the latent infection once established. This finding strongly indicated that latent herpes simplex virus in mice can exist in a nonreplicating form.
Mice, inoculated subcutaneously in the pinna with a suitable strain of herpes simplex virus (HSV), undergo an infection which closely resembles the human disease (7) and forms a convenient model for the study of antiviral chemotherapeutic agents. Concentrations of infectious virus in the ear may be followed by testing tissue homogenates, and the results of these titrations are found to give reproducible patterns of virus growth declining to undetectable levels in survivors 8 to 10 days after inoculation. Local inflammatory changes produced by the virus can be gauged by measuring ear thickness. Progression of virus into the nervous system evokes neurological signs; the most obvious of these is the development of flaccid paralysis of the inoculated pinna, which fails to respond to mild external stimuli (7) . Subsequently latent virus may be reactivated by explanting and culturing the three cervical ganglia that relate to the sensory nerve supply of the pinna.
The nucleoside analog 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine [aciclovir] ) has been reported to be an effective and extremely selective agent against several herpes viruses both in vitro and in a number of animal models (2, 13) . However, previously published reports of acycloguanosine in vivo have not examined the effect of the drug on the establishment and maintenance of a latent infection with HSV. In our study we have examined in detail the effect of the agent on virus replication in vivo during both the acute and the subsequent latent phase of the infection. To provide additional information on the effects of the drug on infected cells in the nervous system, some experiments were carried out on mice infected by intraneural inoculation.
MATERLALS AND METHODS
Mice. Three-week-old BALB/c female mice were obtained from Bantin and Kingman (Grimston, Aldbrough, Hull, England) and used when they were 4 weeks old.
Virus strains. The principal virus used was HSV-1 (SC-16), a clone of the type 1 strain of herpes simplex virus, isolated by S. K. R. Clarke (Public Health Laboratory, Bristol, England) from an oral lesion (7) .
The strain of pseudorabies virus (N,A-2) was originally obtained from J. B. McFerran, Veterinary Research Division, The Farm, Stormont, Belfast, N. Ireland, and shown to be highly virulent for mice (4) .
The thymidine kinase-deficient mutant used in this study was Cl(101)TK- (6) . This is a mutant of HSV-1, originally isolated by Dubbs (14) .
For reactivation experiments the proportion of calf serum was reduced to 2%.
Preparation and adnistration of the drugs. The compounds were received as dry powders from Wellcome Research Laboratories, Research Triangle Park, N.C. They were suspended in distilled water at 3.2 or 1.6 mg/ml; the suspension was briefly sonically disrupted before use and administered either subcutaneously (s.c.) or intraperitoneally (i.p.) in twice-daily injections to give a total dose of 25, 50 or 100 mg/kg per day. Preliminary work had indicated that a daily dose of 50 mg of acycloguanosine per kg per day produced a marked effect on the clinical signs in HSVinfected mice. In earlier experiments the compounds were given s.c. into the scruff of the neck, but this was found inconvenient when handling large numbers of mice. Later, compounds were given i.p.; comparisons of the effectiveness of the two routes of administration showed no differences between the s.c. and the i.p. routes. No specific tests were carried out on the toxicity of acycloguanosine for mice. However, no abnormal signs were observed during 1 month of continuous daily treatment with 100 mg/kg per day i.p., the highest dose employed in these studies.
Inoculation of the mice and virus growth in mouse ear. A 20-pl volume of virus suspension was inoculated intradermally into the left pinnae of anaesthetized 4-week-old mice (7) . To study the replication of virus in ears, the left pinnae were cut off from groups of mice, and the tissue from each mouse was then minced with scissors and ground in 1 ml of ETC in a small glass grinder. The suspensions were then diluted for independent assay using BHK cells (12 
RESULTS
Effects of acycloguanosine on primary infection in the pinna. Mice were inoculated with 10' or 105 PFU of virus and divided into four groups treated with the following compounds: (i) acycloguanosine; (ii) 2,6-diaminopurine; (iii) 2,6-diaminopurine arabinoside, approximately equal in effect to 9-fl-D-arabinofuranosyladenine in animal models (3) , and (iv) untreated. In each case the drug was administered s.c. in twice-daily doses (at 9 a.m. and 6 p.m.) commencing the day before virus inoculation and continuing for 10 days thereafter. The larger inoculum produced a more severe disease in untreated mice with overt signs of neurological involvement. The lower inoculum of 104 PFU per mouse usually produced a nonlethal disease and thus resembled more closely the natural human infection. Acycloguanosine ameliorated the course of the disease, as judged by clinical signs and the titers of infectious virus obtained from ear homogenates on day 3 after inoculation, which was the expected peak of virus multiplication (Table 1 , columns I, II, and III). Only samples from the acycloguanosine-treated mice showed a striking reduction in virus titer from the untreated controls. For comparison, the drug was given in similar doses to mice inoculated with 104 PFU of the herpes virus pseudorabies (which was found to be nonsusceptible to the drug in vitro) into the pinna, but it had no effect on the course of the disease in this case, and all the mice died.
The effectiveness of acycloguanosine was followed throughout the period of the acute disease by taking samples of ear tissue from mice on successive days (Fig. la) . The development of ear thickness in the same mice is shown in Fig.  lb ; twice-daily treatment was continued throughout the experiment. The measurement of ear thickness was also used to examine the effects of commencing or terminating drug treatment during the acute phase (Fig. 2) . After an input of 104 PFU, treatment begun 3 days after infection prevented further marked increase in ear thickness (Fig. 2a) . When treatment (started before inoculation) was terminated 2 days after virus inoculation, this short period of administration still produced a considerably ameliorating effect. Similar results were obtained using the larger inoculum of 105 PFU (Fig. 2b) . The rapid ameliorating effects of acycloguanosine suggested that there might be nonspecific effects on inflammation; similar effects of reduced ear thickness, however, could not be demonstrated in acycloguanosine-treated mice in which ears were inflamed by injection of endotoxin, heatkilled HSV-1 (SC-16), or the thymidine kinasedeficient mutant Cl(101)TK-, or by topical treatment with the contact-sensitizing agent oxazalone. From these tests it was concluded that the effects of the drug described above resulted principally from reduced virus multiplication.
It was noted (as shown in Fig. la ) that infec- The third possibility is that the virus interacts with a population of cells which are less susceptible to the drug. This is discussed later.
Effects of acycloguanosine on the establishment of neurological infection. After replication in the epidermal tissue of the pinna, virus progresses probably by axonal flow (5, 8) to the sensory ganglia supplying the ear, in particular the second, third, and fourth cervical ganglia. In the experiment in which 10' PFU was inoculated the drug was seen to prevent the appearance of clinical signs of neurological involvement (Table 1 , columns I and II). Nevertheless, virus was detected qualitatively in ganglia removed from these mice on day 3 (Table 1 , column IV) in both treated and untreated mice. Acycloguanosine treatment was continued until day 10 after inoculation, and then, 2 weeks later, the second, third, and fourth cervical ganglia were tested qualitatively for the presence of latent virus. The results of these isolations are shown in Table 1 (column V). The remaining mice inoculated with 104 PFU were also checked for the presence of latent virus by quantitative assay 6 days after explanation; the animals were sampled 7 weeks and 10 weeks after inoculation. These results and those of another experiment in which the drug was given i.p. are shown in Table 3 . There was evidence for reduction in the establishment of latency in these three experiments, particularly marked in the last.
The observation that latent infection could be 556 FIELD ET AL.
ANTIMICROB. AGENTS CHEMOTHER. 0) Effect of acycloguanosine on infection by intraneural inoculation. The experiments described above had not proved that acycloguanosine is effective within the peripheral nervous system. Although reduced neurological involvement was observed in the primary infection, this might have been explained by the effects of the drug on local virus replication in the skin, reducing the supply of virus into the nervous system. Experiments were therefore carried out in which virus was injected intraneurally. By inoculation directly into sciatic nerve it was hoped to produce a neurological infection that did not require prior virus replication in non-neurological tissue. The results of these experiments, in which treatment was commenced either the day before virus inoculation or 3 h after inoculation ( Table 5 ), showed that acycloguanosine was highly effective in reducing both clinical signs and levels of infectious virus in several neurological tissues: sciatic nerve, spinal cord, and the first sacral and IV, V, and VI lumbar dorsal root ganglia. It was concluded, from the marked reductionis in virus titer observed in these tissues from drug-treated mice, that adequate levels of the drug were available within these tissues, and in particular within the dorsal root ganglia, to affect virusinfected cells within the peripheral nervous system. Eight intraneural-infected, drug-treated mice were also tested for latency by subsequent explantation of the lumbar-sacral ganglia, and 558 FIELD ET AL.
ANTIMICROB. AGENTS CHEMOTHER. The persistence of virus in the ear and the nature of the late peak of virus activity observed on day 5 was not elucidated, but it could not be attributed to the development of resistance to acycloguanosine. Of various possible mutations to drug resistance, mutants lacking thymidine kinase have been studied, and two of these, obtained artificially have been found by us to show extremely low virulence in the mouse model (6) . Perhaps a more likely explanation is that there are scattered cells in which the virus replicates in the ear but which are less susceptible to the action of the drug either because of reduced permeability, because of differences in their thymidylate metabolism, or because the virus in them is not undergoing the lytic replication cycle.
The observation that latency was established despite treatment would be consistent with and probably reflects the reduction of virus titers observed in the ear during week 1 of the infection. We believe that latency can be established (though less reproducibly) with comparatively (9) . In this situation, some latently infected cells may become susceptible to the activity of the drug, and it is interesting to speculate that after several such recurrences the reservoir of latently infected cells might be destroyed. Work is now in progress to test these possibilities in the mouse ear model.
